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What’s new? 
 We have performed the first meta-analysis evaluating the effectiveness of testosterone 
therapy on a range of sexual function domains in men with Type 2 diabetes.   
 Evidence to date suggests that testosterone therapy may improve sexual desire and 
erectile function in men with Type 2 diabetes; however, heterogeneity among the 
results of included studies, limited participant numbers, and possible reporting bias 
greatly weaken these inferences.  
 We conclude that testosterone therapy could be considered for men with Type 2 
diabetes non-responsive to phosphodiesterase-5 inhibitors when risks and benefits of 
therapy are carefully considered, and other therapeutic options are unsuitable.  
Abstract 
Aim  To evaluate the effectiveness of testosterone therapy on a range of sexual function 
domains in men with Type 2 diabetes. 
Method  Electronic databases were searched for studies investigating the effect of 
testosterone therapy on sexual function in men with Type 2 diabetes. All randomized 
controlled trials were considered for inclusion if they compared the efficacy of testosterone 
therapy with that of placebo and reported sexual function outcomes. Statistical analysis was 
performed using a random-effects model, and heterogeneity was expressed using the I
2
 
statistic. 
Results A total of 611 articles were screened. Six randomized control trials, in a total of 587 
men with Type 2 diabetes, were eligible for inclusion. The pooled data suggested that 
testosterone therapy improves sexual desire (random-effects pooled effect size 0.314; 95% CI 
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0.082–0.546) and erectile function (random-effects pooled effect size 0.203; 95% CI 0.007–
0.399) when compared with control groups. Testosterone therapy had no significant effect on 
constitutional symptoms or other sexual domains compared with control groups. No studies 
have investigated the incidence of prostate cancer, fertility and cardiovascular disease after 
testosterone therapy in men with Type 2 diabetes. 
Conclusion Testosterone therapy may moderately improve sexual desire and erectile 
function in men with Type 2 diabetes; however, available data are limited, and the long-term 
risks of testosterone therapy are not known in this specific patient group. We conclude that 
testosterone therapy is a potential treatment for men with Type 2 diabetes non-responsive to 
phosphodiesterase-5 inhibitors. Testosterone therapy could be considered for men with Type 
2 diabetes when potential risks and benefits of therapy are carefully considered and other 
therapeutic options are unsuitable. 
 
Introduction 
Erectile dysfunction affects 35–90% men with Type 2 diabetes, and has important 
clinical consequences, including reduced quality of life for people with diabetes [1–5]. 
Phosphodiesterase-5 (PDE-5) inhibitors are an effective and generally safe treatment for men 
with erectile dysfunction [6], but a significant proportion of men with Type 2 diabetes have 
ongoing sexual dysfunction which is refractory to PDE-5 inhibitor therapy [7,8]. 
Furthermore, PDE-5 inhibitors have been reported to have significantly lower treatment 
success rates in men with diabetes when compared with men without diabetes [9]; thus, there 
exists a clinical need for second-line treatments for sexual dysfunction in men with Type 2 
diabetes. 
Hypogonadism is a cause of sexual dysfunction which is commonly defined as a total 
serum testosterone <3.2 ng/ml (11 nmol/l) and free testosterone <64 pg/ml (220 pmol/l), with 
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at least three sexual symptoms [6,10]. Cross-sectional studies have reported an association 
between low testosterone and Type 2 diabetes since the early 1990s [11]. Recent published 
studies have reported that up to 40% of men with Type 2 diabetes have testosterone 
deficiency. Type 2 diabetes might cause testosterone deficiency through several mechanisms. 
These include insulin resistance, hyperglycaemia, visceral fat, nutritional status and high 
triglyceride levels [11,12]. In summary, many men with diabetes and erectile dysfunction 
remain refractory to PDE-5 inhibitor treatment, but we know that concurrent hypogonadism 
is common in men with Type 2 diabetes. A strong theoretical argument exists, therefore, for 
using testosterone therapy to treat erectile dysfunction in men with diabetes unresponsive to 
PDE-5 inhibitors.  
Consistent with the physiological actions of testosterone, testosterone therapy is 
known to inhibit spermatogenesis, increase haematocrit levels and stimulate prostatic growth; 
it is therefore imperative to ensure that any indication of testosterone therapy avoids the 
potential risks of fertility, cardiovascular disease and prostate cancer [13,14]. Men with Type 
2 diabetes and erectile dysfunction are often middle-aged or elderly, so have an a priori 
increased risk of cardiovascular disease and prostate cancer. Recently, a number of studies 
have been published investigating the effects of testosterone therapy on sexual dysfunction in 
men with Type 2 diabetes. The aim of the present systematic review and meta-analysis was to 
assess collectively the available evidence to determine the suitability of testosterone therapy 
for the treatment of sexual dysfunction in men with Type 2 diabetes [15]. 
 
Materials and methods 
Study search strategy and selection 
We registered our protocol in advance on the PROSPERO database (reference: 
2017:CRD42017060835). A systematic search was performed in accordance with the Preferred 
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Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [16]. To 
identify eligible studies, we conducted a systematic search of the literature using the 
electronic databases MEDLINE (1966 to August 2016), EMBASE (1988 to August 2016), 
Cochrane CENTRAL (inception to August 2016), Google Scholar, WHO international 
Clinical Trials Registry Platform Search Portal and clinicaltrials.gov. Recent conference 
proceedings and article references were also hand searched for all relevant studies. The 
search terms used were ‘diabetes mellitus’, ‘impotence, ‘erectile dysfunction’, 
‘hypogonadism’, ‘testosterone’ and ‘trial OR RCT’. The search was rerun in April 2017.  
Articles published in any language were included if: (i) they included adult men (aged ≥18 
years) with Type 2 diabetes, irrespective of disease duration or background antidiabetic 
therapy, who were either eugonadal or hypogonadal; (ii) they were randomized controlled 
clinical trials (RCTs) comparing testosterone with placebo; and (iii) the outcomes of each 
study included sexual measurements. We excluded studies that compared testosterone 
therapy with other agents or included people with metabolic syndrome or without diabetes. 
 
Data extraction and quality assessment 
Two independent authors (M.A. and P.M.) screened abstracts, titles and full-text 
publications for eligibility. Discrepancies were adjudicated by a third author (C.J.). Authors 
were emailed to obtain unpublished data and, where possible, these were included. For each 
study, the following data were identified: study reference details; publication date; study 
location; study design; number of participants; intervention; dose and route of administration; 
duration of treatment; randomization; allocation; blinding; withdrawals and drop-outs; and 
mean and SD values at baseline and post-treatment for all variables related to sexual function. 
In some cases, the mean and SD values were not reported, so the authors were contacted and 
the information retrieved [17]. The methodological quality of the included studies was 
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assessed using the criteria proposed by Jadad et al. [18].  
 
Statistical analysis 
Statistical analysis was performed using Comprehensive Meta-Analysis Version 2 by 
an independent statistician. Applying the method of Hedges and Olkin, the treatment effect 
size and 95% CI was calculated for each study [19]. The mean difference for each study was 
divided by the pooled estimate of the SD in order to define the effect size in each study by a 
common metric, most notably the standardized mean difference (SMD), as different scales 
were used among the studies. Effect sizes were then reported as SD units. Compared with 
control groups, this measure expresses the amount of active treatment and how it influences 
the distribution in the outcome of interest. Cohen offers these guidelines in assessing 
treatment effect size: small ~0.2; medium ~0.5; and a large effect size ~0.8. Cohen’s 
guidelines can be used both in judging the treatment effect size of individual studies and/or 
the treatment effect size of all studies combined. As heterogeneity was expected in the effect 
between studies, we used the random-effects model. Statistical heterogeneity was assessed 
using the chi-squared test and was expressed as the I
2
 index, as described by Higgins and 
Green.  P values < 0.05 and I
2
 values >50% were taken to indicate statistical significance 
[20]. 
 
Results 
Search results 
A total of 611 articles were identified from the literature search (Fig. 1) with 14 
studies confirmed to be eligible. Of these, eight studies were excluded for the reasons shown 
in Fig. 1 and six RCTs were identified [17,21–25], with four eligible for inclusion in the 
meta-analysis [17,23–25]. The risk of bias of the studies is shown in Table 1 [17,23–25]. 
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Authors of all studies included in the meta-analysis were contacted; two authors replied 
[17,22], and one author was able to provide further data requested (mean and SD summary 
data) [17].  
 
Study characteristics 
Six RCTs including a total of 587 men with Type 2 diabetes were assessed to evaluate 
the effectiveness of intramuscular testosterone therapy on sexual function between mid-2006 
and 2016  (Table 2 [17,21–25]). Placebo-controlled double-blind trials were used in six of the 
studies (two of them were crossover studies) [17,21–25]. Three trials were conducted in 
Europe [21,23,24] and the remaining three were conducted in India [22], Australia [17] or the 
USA [25]. The mean follow-up ranged between 3 and 12 months. Participants ages were 
similar across the studies, ranging between 44 and 64 years. Testosterone therapy was 
administered in different regimens (Table 2). The mean level of testosterone in participants 
ranged from 9 to 10.6 nmol/l. Researchers used questionnaires and scales investigating the 
character of one or more sexual functions, with adequate evidence of validity and reliability 
[26,27]. All the relevant data provided in the trials were reported as mean with SD values.  
Effects of testosterone treatment on sexual function 
Three RCTs in our analysis measured sexual behaviour and/or dysfunction [23–25]. 
Hackett et al. [24] and Jones et al. [23] enrolled men with Type 2 diabetes and confirmed 
hypogonadism in addition to other symptoms attributed to androgen deficiency; however, 
Dhindsa et al. [25] included men with Type 2 diabetes and confirmed biochemical 
hypogonadism, without any selection for  symptoms of sexual dysfunction. 
Meta-analysis was performed to examine if testosterone therapy improved each of 
five questionnaire-based indices of sexual function in men with Type 2 diabetes (Fig. 2) [23–
25]. Testosterone therapy significantly improved erectile function (pooled effect size 0.203, 
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95% CI 0.007–0.399; P=0.042, I2=0%) and sexual desire (pooled effect size 0.314, 95% CI 
0.082–0.546; P=0.008, I2=21.5%); however, it did not significantly improve orgasmic 
function (pooled effect size 0.236, 95% CI 0.604 to –0.132; P=0.209, I2=69%), intercourse 
satisfaction (pooled effect size 0.453, 95% CI 0.937 to –0.032; P=0.067, I2=79%) or overall 
satisfaction (pooled effect size 0.0085, 95% CI 0.289 to –0.118; P=0.41, I2=0%).  
 
Effects of testosterone treatment on constitutional symptoms 
The Aging Male Symptom score was used to assess constitutional symptoms in three 
RCTs [17,23,24], which included a total of 452 men (224 for testosterone therapy and 228 for 
control). Across all three trials, the pooled estimate suggested a consistent, non-significant 
effect of testosterone on symptom scores [pooled effect size, –0.115; 95% CI –0.299 to 
0.070; I
2
=0% (Fig. 3)].  
 
Safety of testosterone treatment 
Testosterone therapy stimulates haemopoiesis and therefore may be associated with 
thromboembolic disease. Furthermore, controversy surrounds the potential association of 
testosterone therapy with prostate cancer. No cases of thromboembolic disease, fertility or 
prostate cancer were reported in any of the included studies; however, most of the retrieved 
studies investigated a duration of testosterone therapy of ≤6 months, so cannot address the 
long-term safety of testosterone therapy in men with Type 2 diabetes [21,22,25]. 
 
Discussion 
This is the first meta-analysis of randomized studies investigating the effects of 
testosterone therapy on sexual function in men with Type 2 diabetes, and the results suggest 
that testosterone therapy may increase sexual desire and erectile function in men with Type 2 
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diabetes;  however, we recognize that evidence supporting these conclusions is only moderate 
in strength.  
Levels of serum total and free testosterone decline gradually with age in the general 
male population, but there remains considerable debate as to the severity of hypogonadism 
appropriate for the initiation of testosterone therapy [14]. Symptoms of sexual dysfunction 
play an important role in helping clinicians decide if testosterone therapy should be initiated; 
however, it can be more challenging to diagnose symptomatic hypogonadism in men with 
Type 2 diabetes, who commonly have erectile dysfunction for reasons other than testosterone 
deficiency. The mainstay of treatment of sexual dysfunction in men with Type 2 diabetes is 
PDE-5 inhibitor administration. A large number of men with Type 2 diabetes, however, are 
refractory to PDE-5 inhibitor treatment [6,7]. Considering that Type 2 diabetes is reported to 
increase the risk of hypogonadism, it is plausible that a proportion of men with Type 2 
diabetes refractory to PDE-5 inhibitor treatment would be responsive to testosterone therapy.  
Serum levels of testosterone are subject to diurnal variation, and are suppressed by 
ingestion of food. None of the studies included in the present analysis used the 'gold standard' 
method of measuring serum testosterone during two, fasted 09:00 h serum venepunctures 
[28,29]. We therefore cannot exclude the possibility that some participants in the included 
studies had artefactually subnormal serum testosterone levels (so called 'afternoon clinic' or 
'postprandial' hypogonadism). Published evidence on osteoporosis, anaemia and reduced 
testicular volume is needed to support the low serum testosterone levels reported in men with 
Type 2 diabetes who present with hypogonadism.   
For instance, unlike men with objective hypogonadism, there are no data to suggest 
that men with a single randomly low serum testosterone level associated with T2DM 
(representing the preponderance of men recruited to these studies) exhibit either low bone 
density, anaemia or reduced testicular volume at baseline (although testicular volume 
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probably shrinks with testosterone therapy). 
Testosterone promotes male sexual desire. Our results indicate that testosterone 
therapy significantly improved sexual desire in men with Type 2 diabetes, which is consistent 
with previous studies on the general male population [30,31] and men with either Type 2 
diabetes or metabolic syndrome [23,24]. For instance, Hackett et al. [24] observed that 
testosterone therapy improved sexual function in 68 men attending routine clinic 
appointments for Type 2 diabetes who had no sexual activity in the last 12 months.   
Erectile dysfunction can arise during Type 2 diabetes for several reasons other than 
hypogonadism. It is therefore important to consider if testosterone therapy effectively 
improves erectile function in men with Type 2 diabetes. One study in our analysis concluded 
that testosterone therapy significantly improved erectile function [24];  Hackett et al. [24] 
observed, for instance,  that testosterone therapy increased International Index of Erectile 
Function (IIEF) score by 4.31 points from baseline. Furthermore, the IIEF score still 
improved by 2.9 points during testosterone therapy after patients taking PDE-5 inhibitors 
were removed from the analysis. Other studies observed no significant effect between 
testosterone therapy and erectile function [17,23,25]. Overall, our analysis suggests that 
testosterone therapy significantly improved erectile function in men with Type 2 diabetes 
with an effect size 0.203 (95% CI 0.007–0.399), but results of individual studies were 
heterogeneous. Furthermore, there are no long-term data investigating whether testosterone 
therapy confers an increased risk of fertility, prostate cancer or cardiovascular disease. We 
therefore recommend caution when considering long-term testosterone therapy for erectile 
dysfunction in men with Type 2 diabetes. 
A recent meta-analysis evaluating the effect of testosterone therapy on sexual function 
in the general population, concluded that testosterone therapy significantly improved erectile 
function and other aspects of sexual dysfunction compared with placebo, but these effects 
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were less prominent in the presence of metabolic derangement such as diabetes and obesity. 
This result is not surprising as diabetes is often associated with the presence of other 
diabetes-related complications, such as peripheral neuropathy, vasculopathy and endothelial 
dysfunction, which are not directly attributable to androgen deficiency [32,33]. Conversely, 
testosterone therapy is able to improve body composition and insulin resistance in men with 
obesity-related metabolic syndrome and Type 2 diabetes [34,35]. Further studies are required 
to compare directly the effectiveness of testosterone therapy for sexual dysfunction in men 
with and without diabetes.  
In two RCTs included in our analysis, it was observed that testosterone therapy 
improved orgasm or satisfaction with intercourse using the Androgen Deficiency Symptom 
score (ADMS) in men with Type 2 diabetes [21,22]; however, when considering all studies in 
our analysis, there was no overall improvement in orgasm or satisfaction with intercourse 
during testosterone therapy in men with Type 2 diabetes [23–25]. A systematic review of 
RCTs among men without diabetes did show an improvement of orgasm or satisfaction with 
intercourse following testosterone therapy [30,31,36]. Larger studies using a unified 
questionnaire methodology will be important to determine whether people with diabetes do 
have improved orgasm or satisfaction with intercourse using testosterone therapy, or are 
refractory to treatment when compared with men who have normal glucose tolerance. 
Several limitations should be recognized in this systematic review. All studies 
included men with Type 2 diabetes with low levels of serum testosterone, but no unifying 
threshold was used to define testosterone deficiency in the individual studies; this limitation 
reflects the notable clinical controversy that currently surrounds the indications for 
testosterone therapy prescribing, and the potential risks of associated thromboembolic 
disease, fertility and prostate cancer associated with therapy [37–39]. Most of the retrieved 
studies investigated a duration of testosterone therapy of ≤6 months [21,22,25] and involved 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
a small number of participants. It is therefore imperative to conduct large trials further 
delineating the effects of testosterone therapy on sexual function, with long-term follow-up to 
determine adverse events. Published studies seldom report all study outcomes, and often 
under-report outcomes (e.g. describing them as 'non-significant' without presenting the data). 
This reporting bias was addressed by contacting the authors of all included studies and 
requesting the relevant data [17]. 
In conclusion, randomized placebo-controlled trials to date suggest that testosterone 
therapy has a moderate improvement on sexual desire, and a smaller effect on erectile 
function; however, we have highlighted the lack of long-term safety data on testosterone 
therapy in men with Type 2 diabetes. Further research is needed, using validated assessments 
of sexual dysfunction such as IIEF score, evaluation of nocturnal penile tumescence and 
penile colour Doppler ultrasonography, and Androgen Deficiency in the Aging Male 
(ADAM) questionnaires. We conclude that testosterone therapy is a potential treatment for 
men with Type 2 diabetes non-responsive to PDE-5 inhibitors. Testosterone therapy could be 
considered for men with Type 2 diabetes when the risks and benefits of therapy are carefully 
considered, and other therapeutic options are unsuitable. More studies in this area may better 
substantiate the role of testosterone therapy in men with Type 2 diabetes and sexual 
dysfunction, which is sufficient to warrant changes in clinical practice.  
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FIGURE 1 Study selection, based on PRISMA guidelines. n, number of studies. 
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Table 1 Quality assessments of four randomized controlled trials using Jadad score  
 
Items 
Score standard Study 
0 1 2 Dhindsa et 
al. (2016) 
[25]  
Gianatti et 
al. (2014) 
[17]  
Hackett et 
al. (2013) 
[24]  
Jones et 
al. (2011) 
[23]  
Randomization 
Not 
randomized 
Study described 
as randomized 
Randomization 
scheme 
described and 
appropriate 
1 2 2 2 
Double blinding 
No blind or 
inappropriate 
method of 
blinding. 
Study described 
as double-
blind.  
Method of 
double blinding 
described 
appropriately 
1 2 2 2 
Withdrawals and 
dropouts 
Follow-up 
not described 
Description of 
withdrawals 
and dropouts 
given 
/ 1 1 1 1 
Score 
summaries 
/ / / 3 5 5 5 
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 Table 2  Characteristics of the included randomized controlled trials 
 
 
 Study (year) 
 Dhindsa et 
al. (2016) 
[25]  
Gianatti et al. 
(2014) [17]  
Hackett et al. (2013) 
[24]  
Jones et al. (2011) 
[23]  
Gopal et al. (2010) 
[22]  
Kapoor et al. 
(2006) [21]  
Study characteristic       
Location New York, 
USA 
Melbourne, 
Australia 
Multicentre, UK Multicentre, Europe Mumbai, India Sheffield, UK 
Design RCT RCT RCT RCT RCT crossover RCT crossover 
Drugs i.m. 
testosterone 
cypionate 
i.m.  
testosterone 
undecanoate 
i.m.  testosterone 
undecanoate 
testosterone gel 2% i.m.  testosterone 
cyponate 
i.m. sutanon 
Dose 250 mg ⁄ 2 
weeks 
1 g at 0, 6, 18 
and 30 weeks 
1 g at 0, 6 and 18 
weeks 
60 mg ⁄ day 200 mg ⁄ 2 weeks 200 mg ⁄ 2 weeks 
Comparator Placebo Placebo Placebo Placebo Placebo Placebo 
Trial duration, weeks 24  40  30  48  12  12  
Number of participants: 
testosterone group ⁄control group 
20/14 45/43 97/102 108/112 22/22 24/24 
Baseline testosterone therapy, 
nmol/l 
N/A N/A N/A 9.4 10.2 8.6 
Testosterone therapy: testosterone 
group ⁄control group, nmol/l 
9/8.3 10.6/11 10.5/10.8 
7.4/7.2 
9.2/9.5 N/A 8.8/8.1 
Clinical score IIEF AMS IIEF, AMS IIEF, AMS ADAM ADAM 
Mean age, years 55 62 62 60 44 64 
Diabetes duration, years 9 8 N/A N/A N/A N/A 
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HbA1c: testosterone group ⁄control 
group 
mmol/mol 
% 
 
51/ 53 
6.8/7 
 
51/54  
6.8/7.1 
 
59/60 
7.5/7.6 
 
51/59 
6.8/7.5 
 
47/ 60 
6.4/7.6 
 
55/55 
7.2/7.2 
BMI: testosterone group ⁄control 
group, kg ⁄m2  
39/39.5 31.5/33.4 32.8/32.7 32.8/31.2 25.4/22.1 33.2/32.8 
AMS, Aging Male Symptom; IIEF, International Index of Erectile Function; ADAM, Androgen Deficiency in the Aging Male; i.m., intramuscular; N/A, xxx; RCT, randomized controlled trial. 
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